Vascular endothelial growth factor (VEGF) is involved in the pathogenesis of diabetic microvascular disease. Most diabetes patients have higher serum levels of ferritin that may participate in diabetic vascular complications through high oxidative stress induced by iron. However, the mechanistic link between ferritin and VEGF is obscure. The study investigated the association of VEGF and ferritin in patients with diabetic microvascular disease.
Patients and Methods:
Sixty patients with type 2 diabetes mellitus (T2DM) and 26 healthy individuals were selected in this study. Serum ferritin, VEGF, hematological parameters, and clinical data were assessed in this cohort. The Spearman rank method was used to evaluate the associations among them.
Results:
Serum levels of VEGF and ferritin were significantly higher in diabetes patients compared with the controls; levels of both were elevated with development of the disease. There were positive correlations between VEGF and glucose levels and between VEGF and ferritin in diabetes groups, especially in patients with diabetic retinopathy. Positive correlations were also found between VEGF level and the parameters of age, hemoglobin, and albumin in patients with diabetes hypertension.
Conclusions:
Our data suggest that high ferritin levels in T2DM are closely related to the development of diabetic vascular complications through interaction with VEGF.
Get full access to this article
View all access options for this article.
References
1.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 1993; 329:977–986.
2.
MorrishNJ, WangSL, StevensLK, FullerJH, KeenH: Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia, 2001; 44(Suppl 2):S14–S21.
3.
IwashitaN, UchidaT, ChoiJB, AzumaK, OgiharaT, FerraraN, GerberH, KawamoriR, InoueM, WatadaH: Impaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic beta cell-specific vascular endothelial growth factor-A knock-out mice. Diabetologia, 2007; 50:380–389.
4.
WatadaH: Role of VEGF-A in pancreatic beta cells. Endocr J, 2010; 57:185–191.
5.
CostaPZ, SoaresR: Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci, 2013; 92:1037–1045.
6.
AielloLP, WongJS: Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl, 2000; 77:S113–S119.
7.
KrollP, RodriguesEB, HoerleS: Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica, 2007; 221:78–94.
8.
WatanabeT: Is vascular endothelial cell growth factor (VEGF) involved in the pathogenesis of diabetic nephropathy?. Nephrology (Carlton), 2007; 12(Suppl 3):S27.
9.
PathakD, GuptaA, KambleB, KuppusamyG, SureshB: Oral targeting of protein kinase C receptor: promising route for diabetic retinopathy?. Curr Drug Deliv, 2012; 9:405–413.
10.
SandhoferA, TatarczykT, KirchmairR, IglsederB, PaulweberB, PatschJR, SchratzbergerP: Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study. Atherosclerosis, 2009; 206:265–269.
11.
BlancherC, MooreJW, TalksKL, HoulbrookS, HarrisAL: Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res, 2000; 60:7106–7113.
12.
BruickRK, McKnightSL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 2001; 294:1337–1340.
13.
CiudinA, HernandezC, SimoR: Iron overload in diabetic retinopathy: a cause or a consequence of impaired mechanisms?. Exp Diabetes Res, 2010; 2010. pii: 714108.
14.
HarnedJ, FerrellJ, LallMM, FleisherLN, NagarS, GoralskaM, McGahanMC: Altered ferritin subunit composition: change in iron metabolism in lens epithelial cells and downstream effects on glutathione levels and VEGF secretion. Invest Ophthalmol Vis Sci, 2010; 51:4437–4446.
15.
CornaG, SantambrogioP, MinottiG, CairoG: Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem, 2004; 279:13738–13745.
16.
BeardJL: Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr, 2001; 131:568S–579S; discussion 580S.
17.
JiangR, MansonJE, MeigsJB, MaJ, RifaiN, HuFB: Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA, 2004; 291:711–717.
18.
WilsonJG, LindquistJH, GrambowSC, CrookED, MaherJF: Potential role of increased iron stores in diabetes. Am J Med Sci, 2003; 325:332–339.
19.
ValentiL, FracanzaniAL, DongiovanniP, BugianesiE, MarchesiniG, ManziniP, VanniE, FargionS: Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol, 2007; 102:1251–1258.
20.
Fernandez-RealJM, Lopez-BermejoA, RicartW: Cross-talk between iron metabolism and diabetes. Diabetes, 2002; 51:2348–2354.
21.
SullivanJL: Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim Biophys Acta, 2009; 1790:718–723.
22.
ZhengH, CableR, SpencerB, VottoN, KatzSD: Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol, 2005; 25:1577–1583.
23.
PahlPM, YanXD, HodgesYK, RosenthalEA, HorwitzMA, HorwitzLD: An exochelin of Mycobacterium tuberculosis reversibly arrests growth of human vascular smooth muscle cells in vitro. J Biol Chem, 2000; 275:17821–17826.
24.
HalliwellB, GutteridgeJM: Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol, 1990; 186:1–85.
25.
CoffmanLG, ParsonageD, D'AgostinoRJr, TortiFM, TortiSV: Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A, 2009; 106:570–575.
Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 1991; 98(5 Suppl):807–822.
31.
MogensenCE, ChristensenCK, VittinghusE: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes, 1983; 32(Suppl 2):64–78.
32.
1999 World Health Organization–International Society of Hypertension guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens, 1999; 17:151–183.
33.
WredeCE, BuettnerR, BollheimerLC, ScholmerichJ, PalitzschKD, HellerbrandC: Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol, 2006; 154:333–340.
34.
Fernandez-RealJM, Ricart-EngelW, ArroyoE, BalancaR, Casamitjana-AbellaR, CabreroD, Fernandez-CastanerM, SolerJ: Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care, 1998; 21:62–68.
35.
RajpathakSN, CrandallJP, Wylie-RosettJ, KabatGC, RohanTE, HuFB: The role of iron in type 2 diabetes in humans. Biochim Biophys Acta, 2009; 1790:671–681.
36.
MinchenkoA, BauerT, SalcedaS, CaroJ: Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest, 1994; 71:374–379.
37.
SimoR, HernandezC: Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia, 2008; 51:1574–1580.
38.
AntonettiDA, BarberAJ, HollingerLA, WolpertEB, GardnerTW: Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem, 1999; 274:23463–23467.
YuY, WongJ, LovejoyDB, KalinowskiDS, RichardsonDR: Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res, 2006; 12:6876–6883.
41.
CameronNE, CotterMA: Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest, 1995; 96:1159–1163.
42.
QianM, LiuM, EatonJW: Transition metals bind to glycated proteins forming redox active “glycochelates”: implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun, 1998; 250:385–389.
43.
TufroA, VeronD: VEGF and podocytes in diabetic nephropathy. Semin Nephrol, 2012; 32:385–393.
44.
DronavalliS, DukaI, BakrisGL: The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab, 2008; 4:444–452.
